Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus

Lupus

Volumn 19, Issue 11, 2010, Pages 1344-1350

  Zeng, Y J ^a   Zeng, F Q ^a   Dai, L ^a   Yang, C ^a   Lin, B Z ^a   Zheng, D H ^a   Liu, D ^a   Yan, L ^a   Ren, M ^a   Cheng, Hua ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

diabetes mellitus; glucocorticoids; hyperglycemia; impaired glucose tolerance; systemic lupus erythematosus

Indexed keywords

GLUCOCORTICOID; GLUCOSE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CHINESE; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 78649723938     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310375439     Document Type: Article

References (27)

1. Bruce IN 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005 ; 44: 1492-1502.
2. Manzi S., Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997 ; 145: 408-415.
3. Aranow C., Ginzler EM Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000 ; 9: 166-169.
4. Balkau B., Shipley M., Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998 ; 21: 360-367.
5. Coutinho M., Gerstein HC, Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999 ; 22: 233-240.
6. Richard SB Type 2 diabetes: Multiple Treatments for a multicomponent Condition. In. Richard S. Beaser and the staff of Joslin Diabetes Center. eds. Joslin's Diabetes Deskbook: A Guide for Primary Care Providers. 2 nd ed. Lippincott Williams & Wilkins, 2007: 153-170.
7. El MM, Ahmad Y., Turkie W., et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006 ; 33: 50-56.
8. Sada KE, Yamasaki Y., Maruyama M., et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006 ; 33: 1545-1552.
9. Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009 ; 18: 799-806.
10. Vegiopoulos A., Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007 ; 275: 43-61.
11. Bruce IN, Urowitz MB, Gladman DD, Ibanez D., Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003 ; 48: 3159-3167.
12. Haque S., Bruce IN Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005 ; 2: 423-430.
13. Tanay A., Leibovitz E., Frayman A., Zimlichman R., Shargorodsky M., Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann NY Acad Sci 2007 ; 1108: 24-34.
14. Urowitz MB, Gladman D., Ibanez D., et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007 ; 16: 731-735.
15. Cortes S., Chambers S., Jeronimo A., Isenberg D. Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature. Lupus 2008 ; 17: 977-980.
16. Sabio JM, Zamora-Pasadas M., Jimenez-Jaimez J., et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008 ; 17: 849-859.
17. WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications, 2nd ed. Part 1: Diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99. Geneva: World Health Organisation, 1999: 1-59.
18. Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 1725.
19. Zhou BF Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases - report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci 2002 ; 15: 245-252.
20. Uribe AG, Vila LM, McGwin Jr G., Sanchez ML, Reveille JD, Alarcon GS The Systemic Lupus Activity Measure - revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004 ; 31: 1934-1940.
21. Haffner SM, Miettinen H., Gaskill SP, Stern MP Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995 ; 44: 1386-1391.
22. Haffner SM, Kennedy E., Gonzalez C., Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996 ; 19: 1138-1141.
23. Matsuda M., DeFronzo RA Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 ; 22: 1462-1470.
24. Tripathy D., Almgren P., Tuomi T., Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004 ; 27: 2204-2210.
25. Yang W., Lu J., Weng J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010 ; 362: 1090-101.
26. Lillioja S., Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988 ; 318: 1217-25.
27. Raul AC, Barile-Fabris LA, Frati-Munari AC, Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998 ; 29: 259-62.